Proove Biosciences Key Opinion Leaders in the Field Speak on the Genetics of Pain Management
Irvine, CA (PRWEB) March 14, 2016 -- Proove Biosciences, Inc., the commercial and research leader in personal pain
medicine, is pleased to announce that its research was featured at the forefront of a national symposium at the American Academy of Pain Medicine (AAPM) Meeting. Following this symposium, these experts are now featured in an online Pain Management Resource Center, sponsored by Quest Diagnostics.
Three members of Proove’s leading Medical Advisory Board, Dr. Steven Richeimer of USC, Dr. Luda Diatchenko of McGill University, and Lynn Webster, the former President of the AAPM, provide their individual expert opinions on genetic testing and pain medicine in this pain management resource center available online and sponsored by Quest Diagnostics. When asked, “Why do you think it's important to understand genetics and pain medicine,” Dr. Steven Richeimer responded, “I think that's rapidly becoming the future for doctors taking care of patients in chronic pain. The genetics has the potential to give us so much insight into why the patient is dealing with a problem.”
Dr. Diatchenko discusses her thoughts on genetic factors contributing to pain along with the current methods to test for pain sensitivity. These discussions offer insight and answers to many of the unanswered questions associated with chronic pain. Both of these leading expert opinions can be found on The Pain Management Resource Center’s website.
“We are flattered that a lab the caliber of Quest Diagnostics would have an interest in genetic testing in pain medicine,” states Proove CEO Brian Meshkin. “As the leaders in the field with proprietary testing only available through Proove, we believe that this pain management resource center is a validation of the market that we lead and our award-winning clinical research.”
Proove Biosciences’ proprietary bioinformatics platform is protected by 3 issued U.S. patents and additional patents pending. Proove is the only laboratory in the world that offers genetic testing in pain to identify and stratify patient pain sensitivity, as well as genetic testing in pain to identify and stratify patients at risk for the misuse of opioids. There are hundreds of labs that offer drug metabolism genetic testing, but Proove is the only lab that offers such proprietary, patented testing to objectively assess patient pain perception, opioid misuse and NSAID side effect risk, as well as the ability to predict outcomes to leading pain medications.
About Proove Biosciences
Our mission is to change the future of medicine. Proove represents the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could have ever prescribed medications without knowing how a patient would respond. Physicians use Proove Biosciences testing to improve outcomes—both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications.
For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
Genevieve McCormick, Proove Biosciences, http://www.proove.com, +1 949-556-7239, [email protected]
Share this article